Latest On Infinity Pharmaceuticals, Inc (INFI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-03-28 23:05 EST | News | Infinity Pharmaceuticals GAAP EPS of -$0.50 misses by $0.11, revenue of $2.59M misses by $11.31M | N/A |  |
| 2023-02-23 15:52 EST | News | MEI Pharma and Infinity Pharma ink all-stock merger deal | N/A | |
| 2022-11-15 03:29 EST | News | Infinity Pharmaceuticals, Inc. (INFI) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-15 03:29 EST | News | Infinity Pharma falls 24% on Q3 revenue miss | N/A | |
| 2022-11-14 10:11 EST | News | Infinity Pharmaceuticals GAAP EPS of -$0.12, revenue of $0.71M | N/A | |
| 2022-11-12 06:19 EST | News | Infinity Pharmaceuticals Q3 2022 Earnings Preview | N/A | |
| 2022-09-08 12:35 EST | News | Infinity Pharmaceuticals: Waiting For A Deal | N/A | |
| 2022-08-10 18:20 EST | News | Infinity Pharma stock gains ~24% on survival analysis data for a phase 2 trial, Q2 results | N/A | |
| 2022-08-10 01:33 EST | News | Infinity Pharmaceuticals GAAP EPS of -$0.13, revenue of $0.69M | N/A | |
| 2022-08-10 01:32 EST | News | Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-09 03:46 EST | News | Infinity Pharmaceuticals Q2 2022 Earnings Preview | N/A | |
| 2022-05-04 07:51 EST | News | Infinity Pharmaceuticals GAAP EPS of -$0.14 in-line, revenue of $0.65M beats by $0.39M | N/A | |
| 2022-05-04 07:51 EST | News | Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-02 21:32 EST | News | Infinity Pharmaceuticals Q1 2022 Earnings Preview | N/A | |
| 2022-03-30 19:26 EST | News | Infinity Pharmaceuticals stock soars 25% after FY21 revenue beat | N/A | |
| 2022-03-30 02:50 EST | News | Infinity Pharmaceuticals GAAP EPS of -$0.53 in-line, revenue of $1.86M beats by $0.16M | N/A | |
| 2022-03-30 02:50 EST | News | Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-29 02:03 EST | News | Infinity Pharmaceuticals Q4 2021 Earnings Preview | N/A | |
| 2022-01-29 01:51 EST | News | Infinity Pharmaceuticals (INFI) Investor Presentation (Slideshow) | N/A | |
| 2021-12-10 16:46 EST | News | Infinity updates trial data for breast cancer therapy; over 88% achieves cancer reduction | N/A | |
| 2021-11-24 20:55 EST | News | Investigating Infinity Pharmaceuticals | N/A | |
| 2021-11-03 13:43 EST | News | Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-02 17:40 EST | News | Infinity Pharmaceuticals EPS beats by $0.01, misses on revenue | N/A | |
| 2021-11-01 21:14 EST | News | Infinity Pharmaceuticals Q3 2021 Earnings Preview | N/A | |
| 2021-10-18 15:51 EST | News | Infinity Pharma jumps with bullish call from H.C. Wainwright | N/A | |
| 2021-09-07 15:00 EST | News | Infinity Pharmaceuticals names Robert Ilaria as chief medical officer | N/A | |
| 2021-08-02 18:27 EST | News | Infinity Pharma adds another bull at JPMorgan on potential of cancer therapy | N/A | |
| 2021-07-28 23:38 EST | News | Infinity Pharma climbs as Wells Fargo says pullback is "good buying opportunity" | N/A | |
| 2021-07-27 11:22 EST | News | Infinity Pharmaceuticals EPS beats by $0.01, beats revenue; issues guidance | N/A | |
| 2021-07-27 11:22 EST | News | Infinity Pharma updates data from bladder and breast cancer trials | N/A | |
| 2021-07-27 11:21 EST | News | Oragenics, EyeGate Pharmaceuticals leads healthcare gainers; Infinity Pharmaceuticals, NanoVibronix among major losers | N/A | |
| 2021-07-21 11:50 EST | News | Infinity Pharma wins buy rating from B. Riley ahead of key milestone | N/A | |
| 2021-03-18 20:34 EST | News | Translate Bio downgraded after Cystic Fibrosis data; Agilent upgrade and more in today’s analyst action | N/A | |
| 2021-03-18 09:04 EST | Analyst Rating | The Analyst Target Price has increased from $7.6 to $8. | Buy | |
| 2021-03-18 04:57 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-17 21:02 EST | Earnings Estimate | An EPS average of -$0.62 is estimated for the 2022 year. | Sell | |
| 2021-03-17 21:02 EST | Earnings Estimate | An EPS average of -$0.15 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-17 01:59 EST | News | Infinity posts FY results, 2021 forecast | N/A | |
| 2021-03-17 01:59 EST | News | Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-06 15:22 EST | News | This Could Be A Watershed Year For Infinity Pharma Stock | N/A | |
| 2021-02-19 11:44 EST | Analyst Rating | The Analyst Target Price has decreased from $7.75 to $7.6. | Neutral | |
| 2021-02-18 16:18 EST | News | Piper Sandler initiates Infinity Pharmaceuticals at overweight | N/A | |
| 2021-02-15 07:50 EST | Analyst Rating | The Analyst Target Price has increased from $6.5 to $7.75. | Buy | |
| 2021-02-12 19:52 EST | News | Infinity (INFI) shares slide 8% on capital raise | N/A | |
| 2021-02-12 07:56 EST | Analyst Rating | The Analyst Target Price has increased from $4.75 to $6.5. | Buy | |
| 2021-02-12 02:19 EST | News | Infinity Pharma (INFI) gains on promising eganelisib + nivolumab data in urothelial cancer trial | N/A | |
| 2021-02-12 02:18 EST | News | Infinity Pharmaceuticals readies stock offering | N/A | |
| 2021-02-11 08:02 EST | News | Infinity Pharma gains on encouraging eganelisib + nivolumab data in urothelial cancer trial | N/A | |
| 2021-02-10 13:03 EST | News | Infinity loses a fifth ahead of key data readout for eganelisib | N/A | |
| 2021-02-06 03:10 EST | News | Infinity Pharmaceuticals rises ~10% on upgrade indicating 'interesting opportunity' on lead asset | N/A | |
About Infinity Pharmaceuticals, Inc (INFI):
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
General
- Name Infinity Pharmaceuticals, Inc
- Symbol INFI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 25
- Last Split Factor1:4
- Last Split Date2006-09-13
- Fiscal Year EndDecember
- IPO Date2000-07-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.infi.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 113.91
- Price/Book (Most Recent Quarter) 8.03
- Enterprise Value Revenue 165.65
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.53
- Next Year EPS Estimate -$0.59
- Next Quarter EPS Estimate -$0.13
- Operating Margin -2240%
- Return on Assets -54%
- Return on Equity -1839%
- Revenue 1.72 million
- Earnings Per Share -$0.34
- Revenue Per Share $0.03
- Gross Profit 682000
- Quarterly Earnings Growth 41.6%
View More
Highlights
- Market Capitalization 296.92 million
- EBITDA -18712000
- PEG Ratio -0.05
- Analyst Target Price $8
- Book Value Per Share $0.33
View More
Share Statistics
- Shares Outstanding 88.37 million
- Shares Float 56.55 million
- % Held by Insiders 325%
- % Held by Institutions 48.98%
- Shares Short 1.24 million
- Shares Short Prior Month 575387
- Short Ratio 0.18
- Short % of Float 2%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 2.2
- 52 Week High $5.98
- 52 Week Low $0.7
- 50 Day Moving Average 3.48
- 200 Day Moving Average 2.18
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Infinity Pharmaceuticals, Inc (INFI) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Infinity Pharmaceuticals, Inc (INFI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-01 | $436000 | -$0.16 | -$0.16 | 0% |
| 2020-09-30 | 2020-11-09 | $N/A | -$0.16 | -$0.15 | -5.26% |
| 2020-06-30 | 2020-07-30 | $N/A | -$0.16 | -$0.20 | 20.52% |
| 2020-03-31 | 2020-05-11 | $428000 | -$0.19 | -$0.12 | -60.47% |
| 2019-12-31 | 2020-03-03 | $308000 | -$0.20 | -$0.20 | 2.3% |
| 2019-09-30 | 2019-10-30 | $343000 | -$0.20 | -$0.19 | -5.99% |
| 2019-06-30 | 2019-07-30 | $257000 | -$0.18 | -$0.15 | -19.68% |
| 2019-03-31 | 2019-05-07 | $2.14 million | -$0.24 | -$0.16 | -50% |
| 2018-12-31 | 2019-03-14 | $146000 | -$0.26 | -$0.17 | -52.49% |
| 2018-09-30 | 2018-11-05 | $22 million | $0.23 | -$0.15 | 251.62% |
| 2018-06-30 | 2018-08-07 | $N/A | -$0.12 | -$0.20 | 39.42% |
| 2018-03-31 | 2018-05-08 | $N/A | -$0.18 | -$0.18 | 0.72% |
| 2017-12-31 | 2018-03-15 | $N/A | -$0.15 | -$0.25 | 40.36% |
| 2017-09-30 | 2017-11-07 | $6 million | -$0.14 | -$0.20 | 30.86% |
| 2017-06-30 | 2017-08-03 | $N/A | -$0.34 | -$0.20 | -70% |
| 2017-03-31 | 2017-05-09 | $N/A | -$0.21 | -$0.20 | -5% |
| 2016-12-31 | 2017-03-14 | $18.72 million | -$0.46 | -$0.49 | 5.8% |
| 2016-09-30 | 2016-11-09 | $-9467000 | -$0.39 | -$0.85 | 53.85% |
| 2016-06-30 | 2016-08-09 | $9.47 million | -$1.20 | -$0.81 | -47.49% |
| 2016-03-31 | 2016-05-04 | $9.26 million | -$0.82 | -$0.82 | 0.07% |
| 2015-12-31 | 2016-02-23 | $9.08 million | -$0.80 | -$0.88 | 8.61% |
| 2015-09-30 | 2015-11-05 | $90.74 million | $0.84 | -$0.55 | 252.73% |
| 2015-06-30 | 2015-08-06 | $4.88 million | -$0.78 | -$1.00 | 22% |
| 2015-03-31 | 2015-05-06 | $4.36 million | -$1.91 | -$1.68 | -13.69% |
| 2014-12-31 | 2015-02-24 | $4.36 million | -$0.83 | -$0.98 | 15.31% |
| 2014-09-30 | 2014-11-06 | $160.64 million | $2.03 | -$0.86 | 336.05% |
| 2014-06-30 | 2014-08-05 | $N/A | -$0.78 | -$0.84 | 7.14% |
| 2014-03-31 | 2014-05-06 | $N/A | -$0.87 | -$0.83 | -4.82% |
| 2013-12-31 | 2014-02-25 | $N/A | -$0.68 | -$0.87 | 21.84% |
| 2013-09-30 | 2013-11-07 | $N/A | -$0.71 | -$0.74 | 4.05% |
| 2013-06-30 | 2013-08-08 | $N/A | -$0.68 | -$0.62 | -9.68% |
| 2013-03-31 | 2013-05-07 | $N/A | -$0.57 | -$0.69 | 17.39% |
| 2012-12-31 | 2013-03-05 | $47.11 million | -$1.15 | -$0.87 | -32.18% |
| 2012-09-30 | 2012-11-06 | $1000 | $0.52 | -$0.57 | 191.23% |
| 2012-06-30 | 2012-08-07 | $21.91 million | -$0.54 | -$0.38 | -42.11% |
| 2012-03-31 | 2012-05-08 | $25.2 million | -$0.40 | -$0.37 | -8.11% |
| 2011-12-31 | 2012-03-13 | $22.33 million | -$0.53 | -$0.42 | -26.19% |
| 2011-09-30 | 2011-11-08 | $23.31 million | -$0.45 | -$0.42 | -7.14% |
| 2011-06-30 | 2011-08-09 | $19.96 million | -$0.44 | -$0.36 | -22.22% |
| 2011-03-31 | 2011-05-10 | $27.19 million | -$0.09 | -$0.36 | 75% |
| 2010-12-31 | 2011-03-15 | $13.84 million | -$0.53 | -$0.39 | -35.9% |
| 2010-09-30 | 2010-11-09 | $22.5 million | -$0.81 | -$0.76 | -6.58% |
| 2010-06-30 | 2010-08-04 | $18.69 million | -$0.24 | -$0.32 | 25% |
| 2010-03-31 | 2010-05-06 | $16.3 million | -$0.32 | -$0.34 | 5.88% |
| 2009-12-31 | 2010-02-10 | $13.48 million | -$0.30 | -$0.42 | 28.57% |
| 2009-09-30 | 2009-11-09 | $14.08 million | -$0.36 | -$0.44 | 18.18% |
| 2009-06-30 | 2009-08-05 | $13.47 million | -$0.43 | -$0.49 | 12.24% |
| 2009-03-31 | 2009-05-04 | $9.74 million | -$0.15 | -$0.07 | -114.29% |
| 2008-12-31 | 2009-02-09 | $67.05 million | $2.11 | $1.01 | 108.91% |
| 2008-09-30 | 2008-10-29 | $2.5 million | -$0.63 | -$0.54 | -16.67% |
| 2008-06-30 | 2008-08-04 | $2.5 million | -$0.57 | -$0.45 | -26.67% |
| 2008-03-31 | 2008-05-05 | $11.39 million | $0.02 | -$0.36 | 105.56% |
| 2007-12-31 | 2008-02-13 | $5.26 million | -$0.40 | -$0.24 | -66.67% |
| 2007-09-30 | 2007-10-29 | $7.51 million | -$0.10 | -$0.33 | 69.7% |
| 2007-06-30 | 2007-08-01 | $5.65 million | -$0.21 | -$0.29 | 27.59% |
| 2007-03-31 | 2007-04-30 | $6.12 million | -$0.15 | -$0.27 | 44.44% |
| 2006-12-31 | 2007-02-07 | $8.96 million | -$0.27 | -$0.54 | 50% |
| 2006-09-30 | 2006-11-09 | $6 million | -$0.83 | ||
| 2006-06-30 | 2006-08-09 | $2.82 million | -$12.15 | ||
| 2006-03-31 | 2006-05-04 | $719000 | -$1.40 | -$0.56 | -150% |
| 2005-12-31 | 2006-02-21 | -$1.21 | |||
| 2005-09-30 | 2005-11-01 | -$0.16 | -$0.40 | 60% | |
| 2005-06-30 | 2005-08-02 | -$0.20 | -$0.16 | -25% | |
| 2005-03-31 | 2005-05-03 | -$0.72 | -$0.20 | -260% | |
| 2004-12-31 | 2005-03-01 | $0.20 | $0.18 | 11.11% | |
| 2004-09-30 | 2004-11-02 | $0.12 | $0.12 | 0% | |
| 2004-06-30 | 2004-07-20 | $0.12 | $0.12 | 0% | |
| 2004-03-31 | 2004-04-20 | $0.16 | $0.12 | 33.33% | |
| 2003-12-31 | 2004-02-10 | $0.24 | $0.12 | 100% | |
| 2003-09-30 | 2003-10-21 | $0.12 | $0.04 | 200% | |
| 2003-06-30 | 2003-07-22 | $0.04 | $0.02 | 100% | |
| 2003-03-31 | 2003-04-22 | $0.04 | -$0.04 | 200% | |
| 2002-12-31 | 2003-02-11 | $0.04 | -$0.04 | 200% | |
| 2002-09-30 | 2002-10-22 | -$0.12 | -$0.16 | 25% | |
| 2002-06-30 | 2002-07-23 | -$1.60 | -$0.08 | -1900% | |
| 2002-03-31 | 2002-04-23 | -$0.12 | -$0.12 | 0% | |
| 2001-12-31 | 2002-02-12 | -$0.28 | -$0.25 | -12% | |
| 2001-09-30 | 2001-10-30 | -$1.08 | -$1.08 | 0% | |
| 2001-06-30 | 2001-07-31 | -$0.16 | -$0.12 | -33.33% | |
| 2001-03-31 | 2001-05-01 | -$0.36 | |||
| 2000-12-31 | 2001-02-15 | -$0.04 | -$0.09 | 55.56% | |
| 2000-09-30 | 2000-10-31 | -$0.12 | -$0.20 | 40% |
Infinity Pharmaceuticals, Inc (INFI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 7.18 million | N/A | N/A | 7.35 million | N/A |
| Income Before Tax | -10.6 million | N/A | N/A | -10.89 million | -11.38 million |
| Selling General Administrative | 3.23 million | N/A | N/A | 3.32 million | 3.48 million |
| Gross Profit | 173000 | N/A | N/A | 170000 | -8.08 million |
| Ebit | -9.84 million | N/A | N/A | -10.19 million | -11.55 million |
| Operating Income | -10.23 million | N/A | N/A | -10.5 million | -11.55 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | 436000 | N/A | N/A | 428000 | 308000 |
| Cost of Revenue | 263000 | N/A | N/A | 258000 | 8.38 million |
| Total Other Income Expense Net | 277000 | N/A | N/A | 186000 | 172000 |
| Net Income From Continuing Operations | -10.6 million | N/A | N/A | -10.89 million | -11.38 million |
| Net Income Applicable to Common Shares | -10.6 million | -9.53 million | -9.47 million | N/A | -11.38 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | 430000 | 10.27 million | -9.92 million |
| Change to Liabilities | 574000 | 369000 | N/A | 1.29 million | 568000 |
| Total Cash Flow from Investing Activities | -8.99 million | 5.98 million | N/A | 9.5 million | -11.26 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | 19.57 million | 47000 | 38000 |
| Change to Operating Activities | 129000 | 591000 | N/A | 808000 | -307000 |
| Change in Cash | N/A | N/A | 8.23 million | 672000 | -21.04 million |
| Total Cash from Operating Activities | -7.88 million | -7.57 million | -11.78 million | -8.88 million | -9.82 million |
| Depreciation | N/A | N/A | 120000 | 137000 | 64000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 826000 | 822000 | N/A | 272000 | 1.27 million |
| Capital Expenditures | N/A | N/A | 18000 | 767000 | 1.34 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 62.31 million | 61.09 million | N/A | 59.34 million | 41.29 million |
| Total Stockholder Equity | -22.99 million | -14.13 million | N/A | -2.25 million | 7.73 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | 39.32 million | 46.97 million | N/A | 57.09 million | 49.01 million |
| Common Stock | 64000 | 63000 | 57000 | N/A | 57000 |
| Other Current Assets | 234000 | 273000 | N/A | 647000 | 457000 |
| Retained Earnings | -766.32 million | -755.72 million | -746.19 million | -736.72 million | -725.83 million |
| Other Liabilities | 49.83 million | 49.7 million | 49.48 million | N/A | 29.66 million |
| Other Assets | 170000 | 174000 | 328000 | N/A | 530000 |
| Cash | 28.59 million | 18.53 million | N/A | 30.49 million | 22.26 million |
| Total Current Liabilities | 11.05 million | 9.83 million | N/A | 8.46 million | 9.7 million |
| Other Stockholder Equity | -1000 | 10000 | 46000 | N/A | 12000 |
| Property, Plant & Equipment | 3.13 million | 3.32 million | 3.53 million | N/A | 3.9 million |
| Total Current Assets | 36.02 million | 43.48 million | N/A | 53.03 million | 44.58 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -22.99 million | -14.13 million | -11.38 million | N/A | 7.73 million |
| Short Term Investments | 5.52 million | 22.76 million | N/A | 19.86 million | 20.18 million |
| Long Term Debt | 49.58 million | 49.2 million | N/A | 48.73 million | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.98 million | 1.13 million | N/A | 1.36 million | 1.62 million |
Infinity Pharmaceuticals, Inc (INFI) Chart:
Infinity Pharmaceuticals, Inc (INFI) News:
Below you will find a list of latest news for Infinity Pharmaceuticals, Inc (INFI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Infinity Pharmaceuticals, Inc (INFI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest INFI Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $0.7392 |
| Jun 13, 2022 7:59 PM EST | 10 | $0.7415 |
| Jun 13, 2022 7:59 PM EST | 67 | $0.7415 |
| Jun 13, 2022 7:59 PM EST | 43 | $0.7415 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.7415 |
Infinity Pharmaceuticals, Inc (INFI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000023/0001113148-20-000023-index.htm |
| 2018-05-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1113148/000000000018013919/0000000000-18-013919-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1113148/000031506619001123/0000315066-19-001123-index.htm |
| 2018-03-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318006636/0000899243-18-006636-index.htm |
| 2018-04-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318009126/0000899243-18-009126-index.htm |
| 2018-04-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318009133/0000899243-18-009133-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016527/0000899243-18-016527-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016528/0000899243-18-016528-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016529/0000899243-18-016529-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016531/0000899243-18-016531-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016532/0000899243-18-016532-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016533/0000899243-18-016533-index.htm |
| 2018-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016535/0000899243-18-016535-index.htm |
| 2018-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318017943/0000899243-18-017943-index.htm |
| 2018-08-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318021567/0000899243-18-021567-index.htm |
| 2018-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318021568/0000899243-18-021568-index.htm |
| 2018-08-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318022697/0000899243-18-022697-index.htm |
| 2018-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924318025797/0000899243-18-025797-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319000653/0000899243-19-000653-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319000654/0000899243-19-000654-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319000655/0000899243-19-000655-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319000656/0000899243-19-000656-index.htm |
| 2019-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319000660/0000899243-19-000660-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319016999/0000899243-19-016999-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017000/0000899243-19-017000-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017001/0000899243-19-017001-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017002/0000899243-19-017002-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017003/0000899243-19-017003-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017004/0000899243-19-017004-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017005/0000899243-19-017005-index.htm |
| 2019-06-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017006/0000899243-19-017006-index.htm |
| 2019-10-16 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319025626/0000899243-19-025626-index.htm |
| 2019-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924319025628/0000899243-19-025628-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001080/0000899243-20-001080-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001081/0000899243-20-001081-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001082/0000899243-20-001082-index.htm |
| 2020-01-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001083/0000899243-20-001083-index.htm |
| 2020-03-17 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320008609/0000899243-20-008609-index.htm |
| 2020-03-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320008613/0000899243-20-008613-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320016999/0000899243-20-016999-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320017000/0000899243-20-017000-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320017001/0000899243-20-017001-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320017002/0000899243-20-017002-index.htm |
| 2020-06-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000089924320017003/0000899243-20-017003-index.htm |
| 2018-04-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |
| 2018-04-12 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001289/0000921895-18-001289-index.htm |
| 2018-06-21 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001984/0000921895-18-001984-index.htm |
| 2018-06-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2018-11-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2018-11-21 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003134/0000921895-18-003134-index.htm |
| 2018-11-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003181/0000921895-18-003181-index.htm |
| 2018-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003336/0000921895-18-003336-index.htm |
| 2020-01-10 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1113148/000092189520000086/0000921895-20-000086-index.htm |
| 2018-03-15 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1113148/000111314818000004/0001113148-18-000004-index.htm |
| 2018-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314818000007/0001113148-18-000007-index.htm |
| 2018-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314818000010/0001113148-18-000010-index.htm |
| 2018-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314818000013/0001113148-18-000013-index.htm |
| 2019-03-14 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1113148/000111314819000002/0001113148-19-000002-index.htm |
| 2019-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314819000005/0001113148-19-000005-index.htm |
| 2019-07-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314819000008/0001113148-19-000008-index.htm |
| 2019-10-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314819000013/0001113148-19-000013-index.htm |
| 2019-10-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314819000014/0001113148-19-000014-index.htm |
| 2020-03-03 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000004/0001113148-20-000004-index.htm |
| 2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000006/0001113148-20-000006-index.htm |
| 2020-03-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000008/0001113148-20-000008-index.htm |
| 2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000011/0001113148-20-000011-index.htm |
| 2020-04-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000013/0001113148-20-000013-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000016/0001113148-20-000016-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000017/0001113148-20-000017-index.htm |
| 2020-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000021/0001113148-20-000021-index.htm |
| 2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000023/0001113148-20-000023-index.htm |
| 2020-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000027/0001113148-20-000027-index.htm |
| 2020-07-30 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000028/0001113148-20-000028-index.htm |
| 2020-08-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000032/0001113148-20-000032-index.htm |
| 2020-09-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000111314820000034/0001113148-20-000034-index.htm |
| 2018-03-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518074288/0001193125-18-074288-index.htm |
| 2018-03-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518084075/0001193125-18-084075-index.htm |
| 2018-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1113148/000119312518130044/0001193125-18-130044-index.htm |
| 2018-04-30 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1113148/000119312518143468/0001193125-18-143468-index.htm |
| 2018-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518155985/0001193125-18-155985-index.htm |
| 2018-05-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1113148/000119312518156007/0001193125-18-156007-index.htm |
| 2018-06-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518192198/0001193125-18-192198-index.htm |
| 2018-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518203469/0001193125-18-203469-index.htm |
| 2018-08-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518241112/0001193125-18-241112-index.htm |
| 2018-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518288652/0001193125-18-288652-index.htm |
| 2018-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312518318370/0001193125-18-318370-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519003163/0001193125-19-003163-index.htm |
| 2019-01-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519017816/0001193125-19-017816-index.htm |
| 2019-03-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519064709/0001193125-19-064709-index.htm |
| 2019-03-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519074034/0001193125-19-074034-index.htm |
| 2019-03-14 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1113148/000119312519074106/0001193125-19-074106-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519100810/0001193125-19-100810-index.htm |
| 2019-04-24 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1113148/000119312519115859/0001193125-19-115859-index.htm |
| 2019-04-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1113148/000119312519119504/0001193125-19-119504-index.htm |
| 2019-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519139654/0001193125-19-139654-index.htm |
| 2019-06-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519172561/0001193125-19-172561-index.htm |
| 2019-06-14 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1113148/000119312519173034/0001193125-19-173034-index.htm |
| 2019-06-28 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1113148/000119312519186056/0001193125-19-186056-index.htm |
| 2019-06-28 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519186066/0001193125-19-186066-index.htm |
| 2019-07-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519206173/0001193125-19-206173-index.htm |
| 2019-07-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1113148/000119312519206244/0001193125-19-206244-index.htm |
| 2019-08-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312519226878/0001193125-19-226878-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312520004254/0001193125-20-004254-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1113148/000119312520005935/0001193125-20-005935-index.htm |
| 2020-04-03 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1113148/000119312520098113/0001193125-20-098113-index.htm |
| 2020-04-27 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1113148/000119312520120332/0001193125-20-120332-index.htm |
| 2020-06-04 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1113148/000119312520160177/0001193125-20-160177-index.htm |
| 2020-09-21 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1113148/000149315220018037/0001493152-20-018037-index.htm |
| 2018-05-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1113148/999999999518001219/9999999995-18-001219-index.htm |
| 2019-04-29 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1113148/999999999519000894/9999999995-19-000894-index.htm |
| 2018-07-20 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1113148/999999999718006982/9999999997-18-006982-index.htm |
| 2020-02-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1113148/999999999720000781/9999999997-20-000781-index.htm |
| 2020-06-26 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1113148/999999999720003777/9999999997-20-003777-index.htm |
Infinity Pharmaceuticals, Inc (INFI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Infinity Pharmaceuticals, Inc (INFI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 325%Institutional Ownership: 4898%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-08-16 | Jeffery Kutok | Chief Scientific Officer | Sell | 6,133.00 | 2.00 | 12,266.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318022697/0000899243-18-022697-index.htm |
| 2020-01-10 | Seth A Tasker | Chief Business Officer | Buy | 53,538.00 | 101,364.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001083/0000899243-20-001083-index.htm | ||
| 2018-06-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 179,893.00 | 1.65 | 296,823.45 | 1,130,366.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2018-06-21 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 36,825.00 | 1.65 | 60,761.25 | 1,167,191.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2018-11-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 81,648.00 | 1.37 | 111,841.43 | 1,248,839.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 5,573.00 | 1.35 | 7,523.55 | 1,254,412.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-21 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 581.00 | 1.35 | 784.35 | 1,254,993.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-06-12 | ANTHONY B EVNIN | Director | Buy | 11,428.00 | 1.75 | 19,999.00 | 130,013.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016531/0000899243-18-016531-index.htm |
| 2018-06-22 | Jeffery Kutok | Chief Scientific Officer | Sell | 14,313.00 | 2.00 | 28,694.70 | 14,313.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318017943/0000899243-18-017943-index.htm |
| 2019-06-13 | ANTHONY B EVNIN | Director | Buy | 13,125.00 | 1.60 | 21,000.00 | 143,138.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924319017006/0000899243-19-017006-index.htm |
| 2020-06-17 | ANTHONY B EVNIN | Director | Buy | 22,826.00 | 165,964.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924320016999/0000899243-20-016999-index.htm | ||
| 2018-04-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 208,872.00 | 1.90 | 396,856.80 | 3,177,359.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |
| 2018-04-10 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 365,682.00 | 2.00 | 731,364.00 | 3,543,041.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |
| 2018-06-12 | IAN F SMITH | Director | Buy | 22,857.00 | 1.75 | 39,999.75 | 45,845.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016532/0000899243-18-016532-index.htm |
| 2018-04-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 228,691.00 | 1.90 | 434,512.90 | 4,738,476.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |
| 2018-06-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 1,419,907.00 | 1.65 | 2,342,846.55 | 4,962,948.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2018-06-21 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 158,151.00 | 1.65 | 260,949.15 | 5,121,099.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2018-04-10 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 546,865.00 | 2.00 | 1,093,730.00 | 5,285,341.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |
| 2018-11-13 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 562,754.00 | 1.35 | 759,717.90 | 5,683,853.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2018-06-12 | DAVID W BEIER | Director | Buy | 5,714.00 | 1.75 | 9,999.50 | 5,714.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016527/0000899243-18-016527-index.htm |
| 2018-11-14 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 92,960.00 | 1.34 | 124,566.40 | 5,776,813.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2018-11-15 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 39,074.00 | 1.35 | 52,749.90 | 5,815,887.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2018-06-12 | Jeffrey Berkowitz | Director | Buy | 22,857.00 | 1.75 | 39,999.75 | 58,988.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318016533/0000899243-18-016533-index.htm |
| 2018-03-05 | Adelene Q Perkins | Chief Executive Officer | Sell | 5,000.00 | 2.78 | 13,890.00 | 607,252.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318006636/0000899243-18-006636-index.htm |
| 2018-10-01 | Adelene Q Perkins | Chief Executive Officer | Sell | 5,000.00 | 2.82 | 14,100.00 | 609,561.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318025797/0000899243-18-025797-index.htm |
| 2018-08-15 | Jeffery Kutok | Chief Scientific Officer | Sell | 8,180.00 | 2.01 | 16,420.53 | 6,133.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924318022697/0000899243-18-022697-index.htm |
| 2018-11-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 556,709.00 | 1.37 | 762,579.99 | 6,372,596.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 38,001.00 | 1.35 | 51,301.35 | 6,410,597.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-28 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 100,000.00 | 1.30 | 130,000.00 | 6,510,597.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003181/0000921895-18-003181-index.htm |
| 2018-12-13 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 120,539.00 | 1.20 | 144,586.53 | 6,631,136.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003336/0000921895-18-003336-index.htm |
| 2018-06-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 1,916,760.00 | 1.65 | 3,162,654.00 | 7,202,101.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2018-06-21 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 230,555.00 | 1.65 | 380,415.75 | 7,432,656.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001988/0000921895-18-001988-index.htm |
| 2020-01-10 | LAWRENCE E BLOCH | President | Buy | 83,157.00 | 745,094.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001082/0000899243-20-001082-index.htm | ||
| 2018-11-13 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 41,454.00 | 1.35 | 55,962.90 | 7,474,110.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2018-11-14 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 117,290.00 | 1.34 | 157,168.60 | 7,591,400.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2018-11-15 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 52,400.00 | 1.35 | 70,740.00 | 7,643,800.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003077/0000921895-18-003077-index.htm |
| 2020-01-10 | Jeffery Kutok | Chief Scientific Officer | Buy | 64,219.00 | 77,376.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001081/0000899243-20-001081-index.htm | ||
| 2020-01-10 | Adelene Q Perkins | Chief Executive Officer | Buy | 155,134.00 | 793,190.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924320001080/0000899243-20-001080-index.htm | ||
| 2018-11-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 733,151.00 | 1.37 | 1,004,270.24 | 8,376,951.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-19 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 50,044.00 | 1.35 | 67,559.40 | 8,426,995.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-11-21 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 4,119.00 | 1.35 | 5,560.65 | 8,431,114.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003138/0000921895-18-003138-index.htm |
| 2018-12-13 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 54,461.00 | 1.20 | 65,325.97 | 8,485,575.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518003336/0000921895-18-003336-index.htm |
| 2019-06-13 | Jeffrey Berkowitz | Director | Buy | 26,250.00 | 1.60 | 42,000.00 | 85,238.00 | https://www.sec.gov/Archives/edgar/data/1113148/000089924319016999/0000899243-19-016999-index.htm |
| 2018-04-09 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 62,437.00 | 1.90 | 118,630.30 | 853,020.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |
| 2018-04-10 | PARTNERS L P/IL BVF | 10% Share Holder | Buy | 97,453.00 | 2.00 | 194,906.00 | 950,473.00 | https://www.sec.gov/Archives/edgar/data/1113148/000092189518001275/0000921895-18-001275-index.htm |